Introduction
RA is one of the most common systemic autoimmune diseases, and is characterized by synovial inflammation leading to joint destruction if left untreated [1] . A consistent number of patients also experience extra-articular manifestations (EAMs) of RA, including vasculitis and pulmonary involvement, that worsen disease prognosis [2] . Indeed, lung manifestations are the second leading cause of death in patients with RA, cardiovascular disease being the most prevalent [3] . The identification of markers of poor prognosis at the time of disease onset is helpful for clinicians in order to predict a more severe outcome and perform a thorough follow-up along with a prompt and effective treatment.
Historically, RA autoantibodies, namely RF, have been regarded as the most important diagnostic and prognostic serological biomarkers. The subsequent discovery of circulating ACPA in RA patients represented a turning point in the diagnosis and management of the disease. Citrullination of the amino acid arginine, catalysed by peptidil arginine deiminase (PAD) enzyme, is a physiological process that occurs in different tissues thereby altering the structure of several proteins. However, in normal conditions, citrullinated proteins do not trigger an autoimmune response. The breakdown of tolerance to citrullinated self-proteins in genetically predisposed individuals leads to the production of ACPA.
The current gold standard for RA diagnosis is the detection of ACPA in patients' sera with commercially available second-generation ELISA based on synthetic CCP. Anti-CCPs are more specific than RF for RA (9198%), and display a good sensitivity (5183%) [46] . Moreover, it is recognized that anti-CCP positivity identifies a subset of patients with more severe RA characterized by joint destruction and extra-articular involvement [79] . Given that RA is a complex condition, with genetic and environmental factors acting as triggers for autoimmune response, different specificities of RA autoantigens may be helpful to understand the underlying pathogenic mechanism and to identify different clinical subsets.
It is now well established that anti-CCP antibodies are strongly associated with RA genetic and environmental risk factors. In particular, the HLA-DRB1 shared epitope and smoking habit represent the gene-environment trigger in the immune reaction restricted to anti-CCP-positive patients [10, 11] . In this context, the recent discovery of self-protein citrullination in the lung represents the clue to link smoking and RA genetic susceptibility, underlining the relevance of the lung at the very early stage of RA pathogenesis. Several citrullinated proteins have been identified as ACPA autoantigens, including fibrinogen [12] , type II collagen [13] , vimentin [6] EBV-derived citrullinated peptides [6] and alpha enolase. In particular, alpha enolase is a nuclear glycolytic enzyme that in normal conditions acts as inhibitor of oncogene transcription leading to the down-regulation of glycolysis [14] . The evidence that the glycolysis process is enhanced in RA may explain the upregulation of alpha enolase and its susceptibility to citrullination. As far as the immunodominant citrullinated alpha enolase peptide-1 (CEP-1) is concerned, it was identified by Kinloch et al. [15] in RA synovium and SF, the latter reflecting the presence of high serum anti-CEP-1 titre [16] . Two studies identified a strong association between anti-CEP-1 and major susceptibility genetic risk factors of RA (HLA-DRB1, PTPN22) within anti-CCP-positive patients [17, 18] . Interestingly, the strongest interaction between shared epitope, smoking and anti-CCP occurred in anti-CEP-1 -positive patients [17, 18] . Although consistent evidence is available about the possible diagnostic role of anti-CEP-1, little is known about their prognostic value. To date, data regarding the association between anti-CEP-1 and joint erosions are conflicting [18, 19] and no evidence regarding an association between anti-CEP-1 and other EAMs is available.
On this basis, the purpose of our study was to investigate the association between anti-CEP-1 and joint erosions, as well as to explore the association of these autoantibodies and EAMs in a large cohort of Italian patients with RA.
Methods

Patient cohort
Two hundred and fifty-two patients with RA according to the 2010 ACR Classification citeria [20] referring to the Rheumatology Unit of the University of Perugia and the Clinical Immunology and Allergy Unit of the University of Pisa were enrolled. Ninety-seven sex-and age-matched healthy donors (HD) and 50 patients with seronegative SpA acted as normal and disease controls. Serum samples were collected and stored at À20 C until use. Demographic, clinical (including all possible EAMs) and serological records were collected retrospectively through the revision of patient charts. Radiographs of the hands and feet were taken at baseline and repeated yearly to assess the presence/new onset of erosions. Pulmonary involvement, defined as presence of interstitial lung disease (ILD), was ascertained with both X-ray and high resolution CT in patients with respiratory symptoms (n = 37/183). The study was approved by the local Ethics Committee (CEAS Umbria) and all enrolled subjects provided written informed consent according to the Declaration of Helsinki.
Antibody detection
Anti-CCP IgG antibodies were assessed with secondgeneration ELISA kits (either EliA, Thermo Fisher Scientific, Waltham, MA USA or Aeskulisa, Aesku, Wendelsheim, Germany). Anti-CEP-1 IgG antibodies were assessed with a commercially available ELISA kit (Euroimmun, Luebeck, Germany) according to the manufacturers' instructions.
Statistical analysis
Data were processed with SPSS 21.0. Chi-square test, MannWhitney U test and Spearman correlation coefficient were calculated as needed. Values are expressed as mean (S.E.M.) unless otherwise stated. Binary logistic regression was performed to assess the association between the presence of anti-CCP2 and/or anti-CEP-1 antibodies and clinical/serological features. The receiving operator characteristic curve was computed to define the performance of anti-CEP-1 testing.
Results
Anti-CEP-1 positivity distribution in RA and HD Table 1 summarizes the demographic features of patient cohort. As depicted in Fig. 1 , anti-CEP-1 antibodies were significantly more prevalent in the RA cohort compared with HD. In fact, 112 out of 252 RA patients (44%) and 3 out of 97 HD (3%) displayed these antibodies (Chi-square test, P < 0.0001). RA patients also displayed higher antibody titres compared with HD [44.94 (3.7) and 5.1 (0.8), respectively; P < 0.0001]. The prevalence of anti-CEP-1 was similar in RA patients referring to both of the centres (44 and 45%). As far as disease controls were concerned, anti-CEP-1 resulted positive only in one patient with SpA (Chi-square test vs RA, P < 0.0001). Supplementary Fig.  S1 , available at Rheumatology online displays the receiving operator characteristic curves of anti-CEP-1 antibodies using the cut-off value of 20 U/ml as recommended by the manufacturer. When including HD (supplementary Fig. S1A , available at Rheumatology online), the test ensured a specificity of 97% and a sensitivity of 45%.
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The positive predictive value was 97% and the negative predictive value was 40%. Conversely, when including SpA ( Supplementary  Fig.  S1B , available at Rheumatology online) the test showed a specificity of 98%, a sensitivity of 44%, a positive predictive value of 99% and a negative predictive value of 26%. We subsequently evaluated the overlapping of anti-CEP-1 and anti-CCP antibodies. As shown by the Venn diagram of supplementary Fig. S1C , available at Rheumatology online, 97 out of 252 RA patients (38%) displayed both anti-CEP-1 and anti-CCP, while 70 patients (28%) were seronegative for both. Only 15 patients (6%) displayed isolated anti-CEP-1 and 70 patients (28%) displayed only anti-CCP. Thus, patients having anti-CCP antibodies displayed an odds ratio (OR) of 6.5, being positive also for anti-CEP-1 antibodies (95% CI: 3.4, 12; P < 0.0001). In addition, anti-CEP-1 and anti-CCP titres were strongly correlated (Spearman's r= 0.56; P < 0.0001).
Anti-CEP-1 antibodies are associated with erosive disease and RA-associated ILD We subsequently divided patients according to the serological status (both antibodies negative, both antibodies positive, single antibody positive) ( Table 2) . No difference was observed regarding gender, age, age at diagnosis and disease duration. However, a different prevalence of erosive disease was detected among the groups (Chi-square test, P = 0.04). Therefore, we performed binary logistic regression analysis and observed that anti-CCP single positivity, anti-CEP-1 single positivity and anti-CCP/anti-CEP-1 double positivity were associated with erosive disease (OR = 2.1, 4.1 and 2, respectively; P = 0.03, 0.04 and 0.03, respectively) compared with seronegative patients (Table 3) .
We did not observe any difference in the prevalence of any EAM among the four groups using the Chi-square test. However, binary logistic regression showed that anti-CEP-1 single positivity and anti-CCP/anti-CEP-1 double positivity, but not anti-CCP single positivity, were associated with RA-associated ILD (OR = 2 and 2.5, respectively; both P = 0.04) ( Table 3) .
In our cohort, the prevalence of erosive disease and ILD was similar in current/former smokers and non-smokers. With regard to smoking and erosions, no differences in prevalence and titre of anti-CEP-1 were observed between smokers and non-smokers among patients with erosive diseases. Interestingly, however, the distribution and titre of anti-CEP-1 and anti-CCP in smokers/non-smokers with ILD were different. The 75% of smokers with ILD (n = 12) displayed either anti-CCP alone or anti-CCP plus anti CEP-1, whereas only 6% (n = 1) resulted single positive for anti-CEP-1. Conversely, only 20% of non-smokers with ILD displayed either anti-CCP alone or anti-CCP plus anti-CEP-1 (n = 3), but nearly 50% (n = 7) resulted positive only for anti-CEP-1. Furthermore, while the mean anti-CEP-1 titre was comparable in smokers with or without ILD, it was significantly higher in non-smokers with ILD compared with nonsmokers without ILD (P < 0.05). Anti-CEP-1 did not result to be associated with other EAMs or current therapy at binary logistic regression.
Discussion
Over recent years, different ACPA specificities have been identified in RA and their diagnostic and prognostic role has been analysed [21] . However, regarding anti-CEP-1 antibodies, currently available data do not allow definitive conclusions to be drawn. Here we demonstrated for the first time that anti-CEP-1 antibodies are associated with RA-associated ILD and confirmed the observation by Montes et al. that they are also associated with joint erosive disease [18] . Historically, bone erosions have represented a key feature of RA, occurring in over 60% of patients and causing irreversible joint damage, eventually worsening disease prognosis [22] . Indeed, patients with severe and erosive RA are those that are more likely to develop cardiovascular manifestations [23] . The lack of drugs able to interfere with the natural history of the disease has been the main obstacle for clinicians to prevent articular function loss and reduce morbidity and mortality in RA patients. The development of erosions is a multistep process involving immune cells and soluble mediators, culminating with the aberrant activation of osteoclasts and bone resorption. Therefore, persistent chronic inflammation and disease activity are the main determinant of structural damage. Since ACPA positivity is an important determinant of persistent disease activity, an indirect link between ACPA and erosion is easy to find [8, 2427] . However, there is also evidence of a direct link between ACPA and the development of bone erosions. ACPA, indeed, are associated with higher serum levels of RANKL, an activator of osteoclasts [28] , and can activate osteoblasts directly or via their Fc [29] . Furthermore, the evidence that ACPA occurs years before the development of clinically evident articular inflammation and that patients with very early RA may already display erosions, further supports a direct role of these antibodies in this process [24, 3032] . Although many efforts have been spent to identify clinical and serological biomarkers of bone erosion, it still cannot yet be predicted in a consistent proportion of patients and our need for a biomarker able to better stratify patients at higher risk of erosions is compelling. The advent of biologic agents in the 1990s represented a turning point in the management of RA, as the possibility of slowing disease radiographic progression and of increasing erosion-free survival became a reality [22] . Since bone erosions still occur in a high proportion of RA patients, the discovery of biomarkers allowing identification of this patient subgroup from disease onset with a certain degree of confidence is still compelling in order to set up an appropriate follow-up and a prompt therapeutic strategy.
The association between anti-CEP-1 and pulmonary involvement we found in the present study is another intriguing aspect deserving consideration. Although our data confirmed the association between ACPA and erosive disease, we found that RA-associated ILD was more prevalent in patients with single positivity for anti-CEP-1, but not in those with single positivity for anti-CCP. Furthermore, the OR observed in the anti-CCP/CEP-1 double positive and anti-CEP-1 single positive patient subsets was similar. Our results about anti-CCP are in apparent striking contrast to previously published data demonstrating an association of ILD with circulating anti-CCP [9] . In these studies, however, no other ACPA specificities were tested and anti-CCP positivity was globally considered. This may explain, at least in part, the different OR results we observed. In addition, is it interesting to note that half of non-smokers with ILD in our cohort display anti-CEP-1, but not anti-CCP antibodies. It is now well established that cigarette smoke increases the activity of PAD enzyme, the mediator of protein citrullination. A growing number of studies put forward the hypothesis that, since airways are in contact with environmental factors associated with RA, such as cigarette smoke, the initial site of RA autoimmune response may be the lung [22, 33] . Furthermore, there is evidence that smoking is strongly associated with the development of ILD [9, 34] . However, the evidence of ACPA and ILD in non-smokers led to the investigation of other mechanisms behind aberrant citrullination in these subjects. In this regard, the observation that RA appears to be associated with periodontitis induced by Porphyromonas gingivalis, a unique bacterium equipped with the PAD enzyme [35] , is interesting. Intriguingly, Lundberg et al. reported that CEP-1 displays 82% homology with enolase from P. gingivalis and that anti-CEP-1 levels correlate with the levels of antibodies against bacterial peptide. Furthermore, affinitypurified anti-CEP-1 cross-react with citrullinated recombinant P. gingivalis enolase [36] . These data provide strong evidence of pathogenic mechanisms alternative to smoke in ACPA development in RA and may explain the association of anti-CEP-1 antibodies in non-smokers. Furthermore, Seror et al. observed that anti-P. gingivalis antibody titre is significantly higher among RA patients who had never smoked compared with patients who had ever smoked, and among non-smokers, high anti-P. gingivalis antibody levels were associated with a higher prevalence of erosive change [37] . In light of the proven cross-reactivity between anti-CEP-1 and anti-P. gingivalis, it might be speculated that higher anti-CEP-1 titre may be expected in non-smoking RA patients with erosive disease. However, in our cohort we observed a higher anti-CEP-1 titre in non-smoking RA patients with ILD, suggesting a possible link between anti-CEP-1, ILD and P. gingivalis worth further investigation in future studies.
In conclusion, although the cross-sectional nature of our study represents its main limitation, we believe that the novel evidence of an association between anti-CEP-1 and ILD sets out an important point in the seek of the ideal biomarker for EAM in RA. Prospective studies should be planned to investigate the predictive value of anti-CEP-1 in RA.
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